mardi, 29 septembre 2015 14:41

Therachon secures $35 million financing

Published in 2015

The exclusive rights to develop and market a CB1 receptor antagonist for the prevention and treatment of diseases that present with abnormalities in dendritic neurons, and syndrome fragile X, Down syndrome, among others

Published in 2014
Page 1 sur 11